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ABSTRACT 
GWAS have identified a breast cancer susceptibility locus on 2q35. Here we report 
the fine-mapping of this locus using data from 101,943 subjects from 50 case-control 
studies. We genotype 276 SNPs using the “iCOGS” genotyping array and impute 
genotypes for a further 1,284 using 1000 Genomes Project data. All but two, strongly-
correlated SNPs (rs4442975 G/T and rs6721996 G/A) are excluded as candidate 
causal variants at odds >100:1 against. The best functional candidate, rs4442975, is 
associated with estrogen receptor positive (ER+) disease with an odds ratio (OR) in 
Europeans of 0.85 (95% confidence interval = 0.84-0.87; P = 1.7x10
-43
) per t-allele. 
This SNP flanks a transcriptional enhancer that physically interacts with the promoter 
of IGFBP5 (encoding insulin-like growth factor binding protein 5) and displays 
allele-specific gene expression, FOXA1 binding and chromatin looping. Evidence 
suggests that the g-allele confers increased breast cancer susceptibility through 
relative down-regulation of IGFBP5, a gene with known roles in breast cell biology.  
 
The 2q35 breast cancer locus was originally identified in an Icelandic genome-wide 
association study (GWAS)
1
, and subsequently confirmed in larger European studies. 
The largest replication study, comprising 25 studies from the Breast Cancer 
Association Consortium (BCAC), yielded OR of 0.89 (95% CI - 0.87-0.92) per g-
allele for rs13387042 with evidence for association with both ER+ and ER-negative 
(ER-) disease
2
. rs13387042 lies in a 210 kb linkage disequilibrium (LD) block within 
a gene ‘desert’, bounded centromerically by the transition nuclear protein 1 gene 
(TNP1 – 181 kb proximal) and telomerically by the disrupted in renal carcinoma 3 
gene (DIRC3 – 243 kb distal). Additional but more distant centromeric genes are two 
members of the insulin growth factor binding protein family, IGFBP5 (345 kb 
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proximal) and IGFBP2 (376 kb proximal). In the current study, we describe the fine-
scale mapping of the 2q35 breast cancer susceptibility locus using 1,560 genotyped 
and imputed SNPs in 101,943 subjects from 50 case-control studies. The strongest 
candidate for causality, SNP rs4442975, flanks a transcriptional enhancer that 
physically interacts with the promoter of IGFBP5. Furthermore, we demonstrate that 
rs4442975 is associated with allele-specific FOXA1 binding, chromatin looping and 
IGFBP5 expression. Our data suggest that the g-allele of rs4442975 confers increased 
breast cancer susceptibility through reduced IGFBP5 expression.  
 
RESULTS 
Fine-scale mapping identifies two candidate causal variants 
Association analyses were performed on 1,560 2q35 SNPs (276 genotyped and 1,284 
imputed at r
2
>0.3). Three hundred and fifty two SNPs are associated with overall 
breast cancer, 327 with ER+ and none with ER- breast cancer (P-values <10
-4
; 
Supplementary Data 1) in European-ancestry women. The genotyped SNP 
rs4442975 displays the strongest association (per-t allele OR=0.87; 95% CI - 0.86-
0.89; P=3.9x10
-46
; Fig. 1, Table 1 and Supplementary Fig. 1) and this is stronger 
for ER+ disease (OR=0.85, 95% CI - 0.84-0.87; P=1.69x10
-43
) than for ER- disease 
(OR=0.95; 95% CI - 0.91-0.98; P=0.0043; P -heterogeneity=2.8 x 10
-6
; Table 1).  
 
We next conducted multivariable logistic regression for both overall and ER+ breast 
cancer, examining each SNP with univariate P <10
-4
 (N=330) in an analysis adjusted 
for the most significant SNP rs4442975. No further variants are strongly associated 
with overall or ER+ disease. The second most strongly associated SNP for overall 
breast cancer after adjusting for rs4442975 is rs10191184 (OR=0.96; 95% CI=0.93-
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0.99; P=0.0048), consistent with the hypothesis of a single causative variant. We 
compared the log-likelihoods from the ER+ univariate regression models for each 
SNP with the log-likelihood for rs4442975. All SNPs except one (rs6721996), which 
was almost perfectly correlated with rs4442975 (r
2
=0.98) have log-likelihoods >100 
times lower than rs4442975 and hence can reasonably be excluded as being causative. 
The excluded variants include the original GWAS hit, rs13387042, which is strongly 
correlated with rs4442975 (r
2
=0.93) but has odds of 3300:1 against being causative 
(Table 1). Haplotype analyses of the five most strongly associated SNPs identified 
two common and one rarer haplotype (frequency 1.4%: Supplementary Table 1). 
The rare haplotype (1) carries the cancer-protective alleles at rs4442975 (t allele) and 
rs6721996 (a allele), but not rs13387042, and has a similar risk to haplotype 2, 
carrying the protective alleles at all five SNPs, which is consistent with the hypothesis 
of rs4442975 and/or rs6721996 being the causal variant.  
 
In Asian studies the protective alleles for both candidate causal variants (rs4442975 
and rs6721996) are rarer (MAFs=0.13 and 0.12, respectively) than in Europeans 
(MAF=0.49) but their associated relative risk estimates with overall breast cancer are 
consistent: per t-allele OR (rs4442975) =0.94; 95% CI- 0.87-1.02; P=0.12 and per a-
allele OR (rs6721996) =0.95; 95% CI -0.88-1.03; P=0.20 (Table 1).  
 
rs4442975 resides near a putative regulatory element 
We used available ENCODE ChIP-seq data to map the candidate causal SNPs relative 
to transcriptional regulatory elements. SNP rs4442975 lies near a putative regulatory 
element (PRE) as defined by H3K4Me1 histone modifications in 7 cell types from 
ENCODE, and H3K4Me2 in MCF7 cells (Figs. 1 and 2a). This PRE also contains 
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DNaseI hypersensitive sites in both MCF7 and HMEC cell lines (indicative of regions 
of open chromatin) and binds several transcription factors (TFs) associated with 
estrogen signaling
3
 (Fig. 2a). By contrast, the region surrounding SNP rs6721996 
does not contain specific histone modifications or relevant TF binding in the cell lines 
analyzed (Fig. 2a). 
 
rs4442975 alters FOXA1 DNA binding 
Breast cancer susceptibility loci have been shown to be enriched for FOXA1 binding 
sites at active regulatory elements in breast cancer cells; and the 2q35 locus contains 
variants predicted to modulate the affinity of FOXA1
4
. FOXA1 is a pioneer factor and 
master regulator of ER activity due to its ability to open local chromatin and recruit 
ER to target gene promoters
5,6
. SNP rs4442975 is predicted, in-silico, to lie in a 
FOXA1 binding site with the t-allele promoting increased FOXA1-binding compared 
to the g-allele (Figs. 2b and 2c, Supplementary Fig. 2). To assess occupancy of 
FOXA1 in vivo we conducted ChIP followed by allele-specific qPCR in the 
heterozygous BT474 breast-cancer cell-line. We found that FOXA1 is indeed 
preferentially recruited to the t (cancer-protective) allele of candidate causal SNP 
rs4442975 (Fig. 2d and Supplementary Fig. 3). Of note, ChIP-seq data from 
ENCODE identified a second, albeit weaker, FOXA1 binding motif upstream of 
rs4442975 that may also influence FOXA1 recruitment (Fig 2a). However, ChIP-
qPCR did not detect FOXA1 binding in vivo to this additional site, and due to the 
limited availability of FOXA1-positive breast cancer cell lines with the relevant 
genotypes, we are unable to unequivocally discern its affinity for FOXA1. 
Consequently, while our results support a role for rs4442975 in modulating FOXA1 
binding affinity on the site of overlap, we cannot exclude additional cis-effects typical 
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of Multi-Enhancer Variants (MEVs)
7
 where a rare variant, yet to be identified, would 
be in strong LD with the rs4442975 and influence the recruitment of FOXA1 or other 
factors found in the same LD block. 
 
rs4442975 interacts with the IGFBP5 promoter 
To determine the target gene(s) we used chromatin conformation capture (3C) which 
revealed that the PRE containing rs4442975 frequently interacts with the IGFBP5 
promoter (located ~350 kb upstream) in both ER+ breast cancer cell-lines (MCF7 and 
BT474) and in normal breast epithelial cells (MCF10A and Bre-80; Fig. 3a). No 
significant interactions were detected between this PRE and other flanking genes 
including IGFBP2, XRCC5, TNP1 and DIRC3 (Fig. 3a, Supplementary Figs. 4-7). 
The region surrounding SNP rs6721996 did not interact with any flanking genes 
including the IGFBP5 promoter (Supplementary Figs. 4-7). In order to assess any 
potential impact of SNP rs4442975 on this chromatin interaction, allele-specific 3C 
was performed in heterozygous BT474 cell lines. Sequence profiles indicate that the 
rs4442975 t-allele is more strongly associated with looping of this PRE to the 
IGFBP5 promoter than the g-allele (Fig. 3b, Supplementary Fig. 8) suggesting that 
the cancer-protective t-allele may increase IGFBP5 expression through preferential 
contact between this element and the IGFBP5 promoter.  
 
rs4442975 influences IGFBP5 expression 
The regulatory capability of the PRE, combined with the effect of SNP rs4442975, 
was further examined in luciferase reporter assays, using constructs containing the 
IGFBP5 promoter. The wild-type PRE acts as a transcriptional enhancer, leading to a 
2-3-fold increase in IGFBP5 promoter activity (Fig. 3c; PRE REF-G) but inclusion of 
 20 
the rs4442975 t-allele has no significant effect on the PRE enhancer activity (Fig. 3c; 
PRE REF-T). While this appears to rule out an effect of this SNP on transactivation, it 
is possible that rs4442975 is influencing gene expression through other regulatory 
mechanisms. To assess the impact of the rs4442975 alleles on IGFBP5 expression, we 
measured endogenous levels of IGFBP5 mRNA in ER-positive breast cancer cell 
lines either homozygous (G/G) or heterozygous (G/T) for SNP rs4442975. While 
limited in number, the results showed that IGFBP5 mRNA was significantly 
increased in heterozygous cell lines (Figure 4a). Furthermore, given the importance 
of FOXA1 in estrogen-ER activity, we also measured endogenous levels of IGFBP5 
mRNA in MCF7 (G/G) and BT474 (G/T) cells following estrogen induction and 
found that IGFBP5 mRNA was significantly increased but only in the heterozygous 
BT474 cells (Figure 4b, Supplementary Fig. 9). To evaluate allele-specific IGFBP5 
expression, we identified a heterozygous variant (pos271557291) in the first intron of 
IGFBP5 in BT474 cells. Sequencing of the 3C product showed that the t-allele of 
rs4442975 is physically linked to the variant c-allele of pos271557291 
(Supplementary Fig. 10). Allele-specific expression assays revealed that the c-allele 
of variant pos271557291 is preferentially expressed, supporting our conclusion that 
the protective t-allele of rs4442975 is associated with an increase in IGFBP5 
expression (Fig. 4c, Supplementary Fig. 11).  
 
Gene expression analyses in breast tissue 
Finally, we examined the associations of rs4442975 with expression levels of genes 
within 1 Mb of the SNPs, in 123 normal breast tissue samples and 254 breast tumor 
samples in the Norwegian Breast Cancer Study (NBCS), and additionally in 135 
normal breast tissue samples from the Molecular Taxonomy of Breast Cancer 
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International Consortium (METABRIC) study. In normal breast tissue from NBCS, 
SNP rs4442975 is associated expression levels of the IGFBP5 probe, A_23_P154115 
(P=0.045), and similarly in METABRIC with the IGFBP5 probe, ilmn_1750324 
(P=0.026; Supplementary Table 2) but there are no associations with other IGFBP5 
probes used in these studies. In both studies, the protective t-allele of rs4442975 was 
associated with slightly increased IGFBP5 levels (Supplementary Fig. 12). However, 
for each tested IGFBP5 probe there are other more strongly expression-associated 
SNPs (eSNPs) at this locus, none of which are significantly correlated with the breast 
cancer risk candidate SNP, rs4442975 (r2<0.001; Supplementary Table 2). No 
significant associations were observed between rs4442975 and expression of any 
other genes in NBCS normal breast tissues or breast tumors, nor in METABRIC 
normal breast samples (Supplementary Table 3).  
  
DISCUSSION 
In this study, we have conducted a comprehensive analysis of all known common 
variants within a 210kb interval of the original 2q35 locus. We identified one 
independent set of correlated, highly trait-associated variants (iCHAV)
8
 for ER-
positive breast cancer. Our data are consistent with a single disease associated variant, 
with no evidence for further SNPs being associated with breast cancer risk after 
adjustment for the candidate causal SNP, rs4442975. However, we recently identified 
another iCHAV for breast cancer >300 Kb telomeric to rs4442975
9
. These two 
iCHAVs are separated by several recombination hotspots, and their tagging SNPs are 
uncorrelated (r
2
=0.002). This observation fits the general pattern that multiple 
independent cancer susceptibility variants fall within GWAS-identified loci
7,10
, and 
raises the possibility that both associations are mediated through the same target gene.  
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Our allele-specific 3C and expression analyses provided evidence that rs4442975 
contributes to changes in IGFBP5 expression. Although not robustly supported by our 
eQTL studies, two independent datasets showed that the protective t-allele of 
rs4442975 was associated with slightly increased IGFBP5 levels, which is consistent 
with our functional results. However, we also identified other eSNPs in the region that 
are more strongly associated with IGFBP5 expression in normal breast tissue, but do 
not drive breast cancer risk. This situation is not dissimilar to other loci we have 
studied, where we have not found that the causal risk SNPs are strong eQTLs for the 
gene they regulate 
11-13
. This disparity may at least partly be explained by the fact that 
eSNPs are acting in multiple tissues, but risk-associated SNPs may only act in one 
specific cell type. Given that normal breast tissue is so heterogeneous, any eQTL 
effect that is specific to one cell type (such as stem cells) is going to be significantly 
diluted. In addition, eQTLs are very context dependent so might only be expressed in 
breast tissue under particular stimuli or stages of development. It is also possible that 
the relevant cells for the analysis are luminal progenitor cells in adolescence, when 
the human breast seems susceptible to environmental and hormonal influences, but we 
have no access to data from them.  
 
The best understood activity of the IGFBPs is sequestration of extra-cellular IGFs to 
control their growth-promoting actions. IGFBP5, which is expressed in both normal 
and cancer tissues, is a key member of this IGF axis - regulating cellular growth, 
differentiation and apoptosis
14,15
 but IGF-independent actions of IGFBP5 have also 
been demonstrated in various cell types
16,17
. The roles of IGFBP5 in human breast 
cancer are complex and there are many contradictory findings: some lines of evidence 
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suggest that IGFBP5 acts as an inhibitor of tumor growth. For example, Butt et al. 
reported increased expression of IGFBP5 inhibits human breast cancer cell growth
18
. 
Consistent with a pro-apoptotic effect; transgenic mice, expressing IGFBP5 in 
mammary gland, have impaired mammary development and increased apoptotic cell 
death
19
. Other evidence indicates, conversely, that IGFBP5 has anti-apoptotic and 
tumor promoting actions; Perks et al. reported that exogenous IGFBP5 inhibits 
apoptosis of breast cancer cells in vitro
20
. Very low IGFBP5 expression has been 
detected in benign breast epithelium with high expression levels in adjacent breast 
tumor tissue
21,22
.  
 
We propose that the g-allele of SNP rs4442975 (associated with increased risk) 
reduces FOXA1 binding and hence results in reduced chromatin accessibility, 
cofactor recruitment and long-range chromatin interactions. Taken together, all these 
lines of evidence point to increased breast cancer risk, associated with the rs4442975 
g-allele, being mediated through reduced IGFBP5 expression. The IGF axis is already 
an important therapeutic target in other human cancers
23
, and our findings suggest 
further studies on IGFBP5 and breast cancer prevention may be merited.  
 
METHODS 
Study populations and genotyping 
Epidemiological data were obtained from 50 breast cancer case-control studies 
participating in the Breast Cancer Association Consortium (BCAC); these comprised 
41 studies from populations of European ancestry and 9 studies from populations of 
East Asian ancestry
9
. Genotyping was conducted using the iCOGS array, a custom 
array comprising approximately 200,000 SNPs. Details of the participating studies, 
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genotyping calling and quality control are given elsewhere
9
. After quality control 
exclusions, we analysed data from 46,451 cases and 42,599 controls of European 
ancestry and 6,269 cases and 6,624 controls of Asian ancestry. Estrogen receptor (ER) 
status of the primary tumor was available for 34,539 European and 4,972 Asian cases; 
of these 7465 (22%) European and 1610 (32%) Asian cases were ER-negative
9
.  
 
SNP selection and genetic mapping 
We first defined a mapping interval of 210,596 bp (positions 217,732,119-
217,942,715; NCBI build 37 assembly) based on the LD block that included 
rs13387042 in Hapmap (CEU). We catalogued 1,578 variants in the region using the 
1000 Genomes Project (March 2010 Pilot version 60 CEU project data), of which 751 
variants had a minor allele frequency (MAF) > 2%. Of these, we selected all SNPs 
correlated with the rs13387042 at r
2
 > 0.1 (N=150), plus a set of SNPs designed to tag 
all remaining SNPs with r
2
 > 0.9 (N=137). All but 11 SNPs passed a designability 
score (DS) provided by Illumina (DS > 0.9) and were included on the iCOGS array. 
The 276 SNPs included on the array all passed QC and were included in this analysis 
The genotype data were then used to impute genotypes at all additional known SNPs 
in the interval using IMPUTE version 2.0 and the 1000 Genome Project data (March 
2012 version) as a reference panel. One thousand two hundred and eighty four 
variants were successfully imputed, with imputation-r
2
>0.3 in in Europeans. 
 
Statistical analysis 
Per-allele odds ratios (OR) and standard errors were estimated for each SNP using 
logistic regression, separately for subjects of European and Asian ancestry, and 
separately for overall, ER-positive and ER-negative breast cancer. The association 
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between each SNP and breast cancer risk was tested using a 1-degree-of-freedom 
trend test adjusted for study and seven principal components. The statistical 
significance of each SNP was derived using a Wald test. To evaluate evidence for 
multiple association signals, we performed conditional analyses, in which the 
association for each SNP was re-evaluated after including other associated SNPs in 
the model. SNPs with a P-value<10
-4
 and MAF>2% in the single SNP analysis were 
included in this analysis
9
. Differences in the OR between ER-positive and ER-
negative disease were assessed using a case-only analysis, with ER-status as the 
dependent variable. Haplotype-specific odds ratios and confidence limits were 
estimated using haplo.stats
24
. 
 
Cell lines and treatments 
Breast cancer cell lines MCF7 (ER+; ATCC #HTB22), T47D (ER+; ATCC #HTB-
133), ZR751 (ER+; ATCC #CRL-1500), MDAMB415 (ER+; ATCC #HTB-128) and 
BT474 (ER+; ATCC #HTB20) were grown in RPMI medium with 10% FCS and 
antibiotics. MDAMB361 (ER+; kindly provided by Sunil Lakhani, UQCCR, 
Brisbane) were grown in DMEM with 20% FCS and antibiotics. Normal breast 
epithelial cell lines MCF10A (ATCC #CRL 10317) and Bre-80 (kindly provided by 
Roger Reddel, CMRI, Sydney) were grown in DMEM/F12 medium with 5% horse 
serum (HS), 10g/ml insulin, 0.5g/ml hydrocortisone, 20ng/ml epidermal growth 
factor, 100ng/ml cholera toxin and antibiotics. For estrogen induction, 24 h after 
plating MCF7 or BT474 cells into 24-well plates, medium was replaced with that 
containing 10 nM fulvestrant. Cells were incubated for 48 h and then fresh medium 
containing either 10 nM estrogen or DMSO (as vehicle control) was added
25
. All cell 
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lines were maintained under standard conditions, routinely tested for Mycoplasma and 
identity profiled with short tandem repeat markers.  
 
Chromatin conformation capture (3C) 
Breast cancer cell lines were grown to 80% confluence then cross-linked with 1% 
formaldehyde at 37
o
C for 10 min, quenched with ice-cold 125 mM glycine and 
harvested by cell scraping. Cells were then washed twice in ice-cold PBS, lysed for 30 
min on ice in 10 mls lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 0.2% Igepal, 
1X protease inhibitor cocktail), and homogenized with 15 strokes in a Dounce 
homogenizer. Nuclei were then pelleted for 10 min (800g at 4
o
C), washed in PBS and 
resuspended in 1 ml 1.2x EcoRI restriction buffer and 0.3% sodium dodecyl (SDS) 
for 1 h at 37
o
C with shaking. Triton X-100 (2%) was added to sequester SDS, and 
then each tube was digested with 1500U EcoRI for 24 h at 37
o
C with shaking. One 
aliquot of digested cells was set aside to assess restriction enzyme efficiency by real-
time PCR (qPCR), the rest was ligated with 4000U of T4 DNA ligase for 4h at 16
o
C. 
Crosslinks were reversed by proteinase K digestion overnight, and then the 3C DNA 
template was purified by phenol-chloroform extraction followed by four rounds of 
ethanol precipitation. The final DNA pellet was dissolved in 10 mM Tris (pH 7.5) 
overnight at 4
o
C, purified through Amicon Ultra 0.5ml columns (EMD Millipore) and 
quantitated by qPCR. 3C interactions were quantitated by qPCR using primers 
designed within EcoRI restriction fragments (Supplementary Table 4). All qPCRs 
were performed on a RotorGene 6000 using MyTaq HS DNA polymerase with the 
addition of 5 mM of Syto9, annealing temperature of 66
o
C and extension of 30sec. 3C 
analyses were performed in three independent experiments with each experiment 
quantified in duplicate. BAC clones (RP11-96E20, RP11-944D16, RP11-14F16, 
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RP11-639B13, RP11-43F9, RP11-22K2) covering the 2q35 region were used to 
create artificial libraries of ligation products in order to normalize for PCR efficiency. 
Data were normalized to the signal from the BAC clone library and, between cell 
lines, by reference to a region within GAPDH. All qPCR products were 
electrophoresed on 2% agarose gels, gel purified and sequenced to verify the 3C 
product.  
 
Plasmid construction and luciferase assays 
The IGFBP5 promoter-driven luciferase reporter construct was generated by inserting 
a 1071 bp fragment containing the IGFBP5 promoter into the KpnI and XhoI sites of 
pGL3-basic. To assist cloning, AgeI and SbfI sites were inserted into the BamHI and 
SalI sites downstream of luciferase. A 1296 bp fragment containing the PRE was 
inserted into the AgeI and SbfI sites downstream of luciferase. SNP rs4442975 was 
incorporated into the PRE using overlap extension PCR. All constructs were 
sequenced to confirm variant incorporation (AGRF, Australia). Primers used to 
generate all constructs are listed in Supplementary Table 4. MCF7, BT474, 
MCF10A and Bre-80 breast cells were transfected with equimolar amounts of 
luciferase reporter plasmids and 50ng of pRLTK using Lipofectamine 2000. The total 
amount of transfected DNA was kept constant per experiment by adding carrier 
plasmid (pUC19). Luciferase activity was measured 24 h post-transfection using the 
Dual-Glo Luciferase Assay System on a Beckman-Coulter DTX-880 plate reader. To 
correct for any differences in transfection efficiency or cell lysate preparation, Firefly 
luciferase activity was normalized to Renilla luciferase. The activity of each test 
construct was calculated relative to IGFBP5 promoter construct, the activity of which 
was arbitrarily defined as 1.  
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Intra-Genomic Replicates (IGR) 
IGR predicts the modulation in affinity produced by a SNP at a transcription factor 
(TF) binding site
4
. The affinity of a TF for a particular DNA sequence of length K (K-
mer) is obtained by averaging binding data across a ChIP-seq dataset for that TF. IGR 
accounts for displacement effects by computing affinity models over a sliding 
window of K-mers around the SNP of interest. Through this process, the collection of 
affinity models for increasing values of K are placed in a lattice structure that 
connects K-mers that are one base pair apart. Two lattices are constructed, one for 
each of the variants alleles. The maxima among the affinity models in the lattices are 
used to calculate the IGR score. T-tests are used to assess the statistical significance 
of the affinity modulation between the two K-mers with the maximum affinities. 
 
Allele-specific ChIP-qPCR 
Breast cancer cell lines were grown to 95% confluence then cross-linked with 1% 
formaldehyde at 37
o
C for 10 min, cells were then rinsed with ice-cold PBS plus 5% 
BSA and then with PBS, and harvested with PBS plus 1X protease inhibitor cocktail 
(Roche Molecular Biochemicals, Indianapolis, IN). Harvested cells were centrifuged 
for 2 min at 3000rpm. Cell pellet was then resuspended in 0.35 mL of lysis buffer (1% 
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1X protease inhibitor cocktail) and 
sonicated 20 times in 30sec on-30sec off cycles at the maximum setting (Diagenode 
Biorupter 300) followed by centrifugation at maximum speed for 15 min. 
Supernatants were collected and diluted in dilution buffer (1% Triton X-100, 2 mM 
EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1). Four micrograms of FOXA1 
antibody (Acris, AP16139PU-N) was prebound for 6 h to protein A and protein G 
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Dynal magnetic beads (Dynal Biotech, Norway) and washed three times with ice-cold 
PBS plus 5% BSA and then added to the diluted chromatin for overnight 
immunoprecipitation. The magnetic bead-chromatin complexes were collected and 
washed six times in RIPA buffer (50 mM HEPES [pH 7.6], 1 mM EDTA, 0.7% Na 
deoxycholate, 1% NP-40, 0.5 M LiCl), then washed twice with TE buffer. To reverse 
the formaldehyde cross-linking, decrosslinking buffer (1% SDS, 0.1 M NaHCO3) was 
added to the complexes overnight at 65
o
C. DNA fragments were purified with a 
QIAquick Spin Kit (Qiagen, CA). For PCR, 2.5uL from a 125uL immunoprecipitated 
chromatin extraction and 250uL input extraction, and 40 cycles of amplification were 
used. To assess differential FOXA1 binding at the heterozygous alleles, the MAMA 
(Mismatch Amplification Mutation Assays) PCR-based technique was used
26
. 
Reverse MAMA primers specific to each allele were designed with one mismatched 
nucleotide at the 3’ end26. The primers are listed in Supplementary Table 4. 
 
Gene expression analysis  
MCF7 and BT474 total RNA was extracted using Trizol (Life Technologies) from 
untreated, estrogen (10nM) or vehicle (DMSO) treated cells. Residual DNA 
contaminants were removed by DNAse treatment (Ambion) and cDNA was 
synthesized using random primers as per manufacturers’ instructions (Life 
Technologies). All qPCRs were performed on a RotorGene 6000 (Corbett Research) 
with TaqMan Gene Expression assays (Hs00181213_m1 for IGFBP5 and 
Hs00907239_m1 for TFF1) and TaqMan Universal PCR master mix. All reactions 
were normalized against B-glucuronidase (MIM 611499; Cat# 4326320E). For in vivo 
allele-specific gene expression, a primer outside of the rs4442975 SNP and its closest 
EcoRI restriction enzyme site and a primer outside of the SNP pos271557291 and its 
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closest EcoRI site were first used to PCR amplify the EcoRI 3C product from BT474 
cells. PCR amplified products were cloned into pBLUNT empty vector (Life 
Technologies), then sequenced using the Sanger sequencing, which revealed the 
linkage between the two alleles (Supplementary Fig. 10). BT474 genomic DNA was 
extracted using Qiagen DNeasy blood and tissue kit. BT474 total nuclear RNA was 
extracted using Trizol and cDNA synthesized using a gene-specific primer. PCR 
amplified sequences from BT474 genomic DNA or cDNA were gel purified (Qiagen) 
and Sanger sequenced to measure the DNA and RNA level of each allele. All 
experiments were conducted in biological triplicates and qPCR reactions as technical 
duplicates. The primers are listed in Supplementary Table 4. 
 
Expression quantitative trait locus (eQTL) analysis 
eQTL analyses were conducted in two studies:- 
123 normal breast tissue and 254 breast tumors from women in the Norwegian Breast 
Cancer Study (NBCS); all women were of Caucasian origin. The 123 normal breast 
tissue is a cohort of expression data from normal breasts biopsy (n=74), reduction 
plastic surgery (n=37) and adjacent normal (n=12) (adjacent to tumor). Correlations 
between the two most likely causative SNPs (rs4442975 and rs6721996) and 
expression levels of nearby genes (500 kb upstream and downstream of the SNPs) 
were assessed using a linear regression model in which an additive effect on 
expression level was assumed for each copy of the rare allele. Calculations were 
carried out using the eMap library in R (www.bios.unc.edu/~weisun/software/eMap). 
The second eQTL analysis was based on 135 adjacent normal breast samples from 
women of Caucasian origin in the METABRIC study
27
. Matched gene expression 
(Illumina HT-12 v3 microarray) and germline SNP data that was either genotyped 
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(Affymetrix SNP 6.0) or imputed (1000 Genomes Project, March 2012 data using 
IMPUTE version 2.0) were used. Statistical methods were identical to the NBCS 
analysis. 
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FIGURE LEGENDS 
Figure 1. Genetic mapping and epigenetic landscape at the 2q35 locus. Manhattan 
plot of the 2q35 breast cancer susceptibility locus. Genotyped (black dots) and 
imputed (red dots) SNPs are plotted based on their chromosomal position on the x-
axis and their overall P values (log10 values, likelihood ratio test) from the European 
BCAC studies (46,451 cases and 42,599 controls) on the y axis. The shaded region 
represents an area bounded by SNPs correlated with rs4442975 at r
2
=0.8. Data from 
the UCSC Genome Browser, including epigenetic marks for methylation of histone 
H3 at lysine 4 (H3K4me1, H3K4me3) and acetylation of H3 at lysine 27 (H3K27ac) 
in 7 cell types from ENCODE
28
. The positions of all analyzed iCOGS SNPs are 
marked. Linkage disequilibrium, using data from the BCAC population, is depicted 
beneath - white represents r
2
=0, and black r
2
=1. 
 
Figure 2. Allele-specific binding of FOXA1 at the rs4442975 site. (a) Epigenetic 
and transcriptional landscape of the 2q35 risk interval. Coloured histogram denotes 
histone modification ChIP-seq data from ENCODE. Data from the UCSC Genome 
Browser, including epigenetic marks for H3K4me1 in 7 cell types from ENCODE
28
, 
and H3K4me2 from MCF7 cells
4
, DNaseI hypersensitivity clusters in 125 cell types 
from ENCODE
28
, and transcription factor ChIP-seq data from MCF7 and T47D ER+ 
breast cancer cells which are homozygous for the g-allele of rs4442975 and 
rs6721996 (ENCODE). The PRE (putative regulatory element) contains SNP 
rs4442975. (b) Position weight matrix (PWM) of FOXA1 from JASPAR, with 
homology to the risk (g) and cancer-protective (t) alleles of rs4442975 coloured below. 
(c) Intragenomic replicates (IGR) histogram for SNP rs4442975 predicting the 
binding intensity of FOXA1 using a seven nucleotide affinity model
5
. The top row of 
colored numbers shows the number of instances for each K-mer found genome wide 
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within H3K4me2 elements in MCF7 cells. The bottom row shows the averaged 
binding intensities at the K-mers (50 bp window). Control profiles, shown in gray, are 
generated by scrambling the probed sequence. (d) Allele-specific FOXA1 ChIP-qPCR 
results assessed at the rs4442975 SNP in heterozygous BT474 breast cancer cells. 
Error bars denote SD. P values were determined with a two-tailed t test. **p<0.01.  
 
Figure 3. Chromatin interactions at the 2q35 risk region with IGFBP5 in breast 
cell lines. (a) 3C interaction profiles between the PRE (containing rs4442975) and the 
IGFBP5 promoter region (grey box). 3C libraries were generated with EcoRI, with the 
anchor point set at the PRE. A physical map of the region interrogated by 3C is shown 
above, with the grey bar representing the position of the IGFBP5 promoter (not to 
scale). Graphs represent three biological replicates assayed in duplicate. Error bars 
denote SD. (b) 3C followed by sequencing for the rs4442975-containing region in 
heterozygous BT474 breast cancer cells shows allele-specific chromatin looping. 
Chromatograms represent one of three independent 3C libraries generated and 
sequenced. (c) Luciferase reporter assays in breast cell lines demonstrating enhancer 
activity of the PRE at the 2q35 risk locus. The PRE was cloned upstream of an 
IGFBP5 promoter-driven luciferase reporter with and without SNP rs4442975. Cells 
were transiently transfected with each of these constructs and assayed for luciferase 
activity after 24h. Graphs represent two independent experiments assayed in triplicate. 
Error bars denote SD. P values were determined with a two-tailed t test. 
****p<0.0001.  
 
 Figure 4. IGFBP5 expression in breast cancer cell lines and normal breast tissue. 
(a) Endogenous IGFBP5 expression measured by qPCR in untreated ER+ human 
breast cancer cell lines, and (b) estrogen-stimulated breast cancer cell lines. Graphs 
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represent three independent experiments. Error bars denote SEM. P values were 
determined with a two-tailed t test. ****p<0.0001. (c) Allele-specific IGFBP5 
expression measured by allelic amplification of intronic marker variant pos271557291. 
Chromatograms represent one of three independent experiments performed and 
sequenced.  
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TABLE 1 
SNP Position Ref Alt EAF* OR_overall P1df_overall OR_ER- P1df_ER- OR_ER+ P1df_ER+ 
Europeans           
rs4442975 217920769 G T 0.49 0.87 
(0.86-0.89) 
3.91E
-46
 0.95 
(0.91-0.98) 
0.0043 0.85 
(0.84-0.87) 
1.69E
-43
 
rs6721996 217909463 G A 0.49 0.87 
(0.86-0.89) 
7.09E
-45
 0.94 
(0.91-0.98) 
0.0028 0.86 
(0.84-0.88) 
4.02E
-42
 
rs13387042 217905832 A G 0.51 0.88 
(0.86-0.89) 
1.69E
-41
 0.96 
(0.92-0.99) 
0.023 0.86 
(0.84-0.88) 
5.63E
-40
 
Asians           
rs4442975 217920769 G T 0.13 0.94 
(0.87-1.02) 
0.12 1.01 
(0.89-1.14) 
0.90 0.93 
(0.85-1.02) 
0.11 
rs6721996 217909463 G A 0.12 0.95 
(0.88-1.03) 
0.20 1 
(0.89-1.14) 
0.96 0.94 
(0.86-1.03) 
0.2 
rs13387042 217905832 A G 0.12 0.95 
(0.88-1.03) 
0.21 1.01 
(0.89-1.14) 
0.89 0.94 
(0.85-1.03) 
0.18 
           
 
Table 1: Association of the two most strongly associated SNPs (rs4442975 and rs6721996) and the original GWAS SNP (rs13387042) 
with breast cancer. The table displays the per-allele odds ratios for breast cancer in Europeans and Asians, and separately for ER-positive and 
ER-negative disease. In the Asian studies, the protective/rare alleles for these three SNPs are rarer (MAFs=0.13, 0.12 and 0.12, respectively) 
than in Europeans (MAF=0.49) but their associated relative risk estimates with overall breast cancer are consistent: per t-allele OR (rs4442975) 
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=0.94; 95% CI- 0.87-1.02; P=0.12, per a-allele OR (rs6721996) =0.95; 95% CI -0.88-1.03; P=0.20 and per a-allele OR (rs13387042) =0.95; 
95% CI -0.88-1.03; P=0.21. * EAF: Effect Allele Frequency (frequency of the alternative allele relative to the reference allele). 
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